Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy

BACKGROUND: Anti-PD-1 therapy has shown significant clinical activity in advanced melanoma. We developed and validated a clinical prediction scale for response to anti- PD-1 monotherapy. METHODS: A total of 315 patients with advanced melanoma treated with pembrolizumab (2 or 10 mg kg(−1) Q2W or Q3W)...

Descripción completa

Detalles Bibliográficos
Autores principales: Nosrati, Adi, Tsai, Katy K, Goldinger, Simone M, Tumeh, Paul, Grimes, Barbara, Loo, Kimberly, Algazi, Alain P, Nguyen-Kim, Thi Dan Linh, Levesque, Mitchell, Dummer, Reinhard, Hamid, Omid, Daud, Adil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418446/
https://www.ncbi.nlm.nih.gov/pubmed/28324889
http://dx.doi.org/10.1038/bjc.2017.70

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418446/
https://www.ncbi.nlm.nih.gov/pubmed/28324889
http://dx.doi.org/10.1038/bjc.2017.70

Ejemplares similares